I have been sloppy in assuming that typical chemistries, cytokine levels and the like would be collected in S/C patient population. I do not see any indication in the trial description indicating that these will be evaluated as “other outcomes”, as they are in the M/M trial.
I believe, though have no way to know, that these data will be collected in S/C patients as well, even though they are not part of trial as outcome criteria. There is so much to be learned about Covid-19 illness that I find it difficult to believe that these trials will not be exploited for all learning possible. Incredible to me that no one seems to have taken Cytodyn/IncellDx up on offer of free analysis of MIS-C/Kawasaki like disease. Just unfathomable.
I applaud the analysis of the clinical and business developments around Cytodyn that this group is conducting. Unfortunately, the only things about which I am certain is that leronlimab is the real deal and that the waiting as the trials play out are insufferable.
Another opportunity for me to learn better patience.
Thanks to all.
I believe, though have no way to know, that these data will be collected in S/C patients as well, even though they are not part of trial as outcome criteria. There is so much to be learned about Covid-19 illness that I find it difficult to believe that these trials will not be exploited for all learning possible. Incredible to me that no one seems to have taken Cytodyn/IncellDx up on offer of free analysis of MIS-C/Kawasaki like disease. Just unfathomable.
I applaud the analysis of the clinical and business developments around Cytodyn that this group is conducting. Unfortunately, the only things about which I am certain is that leronlimab is the real deal and that the waiting as the trials play out are insufferable.
Another opportunity for me to learn better patience.
Thanks to all.
6
